Hydralazine in the long-term treatment of chronic heart failure

Lack of difference from placebo

Joseph A. Franciosa, Karl Weber, T. Barry Levine, Gary T. Kinasewitz, Joseph S. Janicki, James West, Marc M.J. Henis, Jay N. Cohn

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Although hydralazine improves cardiac performance in patients with chronic left ventricular failure, its long-term clinical efficacy has not been established in controlled trials. We carried out a double-blind randomized trial of hydralazine (200 mg daily in 16 patients) versus placebo (16 patients) in patients with class III and IV symptoms while they were taking digitalis and diuretics. Maximal treadmill exercise time was determined prior to and at 4, 10, 18, and 26 weeks of hydralazine or placebo treatment; average follow-up was 20 weeks. We found no change in body weight, clinical class, resting heart rate and blood pressure, or heart size (by chest x-ray examination and echocardiogram) during treatment in either group. The total number of complicating clinical events was insignificantly fewer in the hydralazine treated group (8 vs 13). Control exercise duration in the hydralazine group averaged 259 ± 21 seconds (SEM), and increased to 347 ± 35 seconds at 4 weeks (p < 0.01) and 421 ± 38 seconds at 26 weeks (p < 0.001). Exercise duration also increased significantly in the placebo group, from 271 ± 30 seconds at control to 340 ± 44 seconds at 4 weeks (p < 0.02) and 339 ± 46 seconds at 26 weeks (p < 0.02). No differences between groups were significant. Left ventricular ejection fraction remained depressed and unchanged in both groups. Thus long-term vasodilator treatment with hydralazine alone is not significantly more effective than placebo in chronic heart failure.

Original languageEnglish (US)
Pages (from-to)587-594
Number of pages8
JournalAmerican Heart Journal
Volume104
Issue number3
DOIs
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Hydralazine
Heart Failure
Placebos
Exercise
Therapeutics
Body Weight Changes
Digitalis
Vasodilator Agents
Diuretics
Stroke Volume
Thorax
Heart Rate
X-Rays
Blood Pressure

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Franciosa, J. A., Weber, K., Levine, T. B., Kinasewitz, G. T., Janicki, J. S., West, J., ... Cohn, J. N. (1982). Hydralazine in the long-term treatment of chronic heart failure: Lack of difference from placebo. American Heart Journal, 104(3), 587-594. https://doi.org/10.1016/0002-8703(82)90231-9

Hydralazine in the long-term treatment of chronic heart failure : Lack of difference from placebo. / Franciosa, Joseph A.; Weber, Karl; Levine, T. Barry; Kinasewitz, Gary T.; Janicki, Joseph S.; West, James; Henis, Marc M.J.; Cohn, Jay N.

In: American Heart Journal, Vol. 104, No. 3, 01.01.1982, p. 587-594.

Research output: Contribution to journalArticle

Franciosa, JA, Weber, K, Levine, TB, Kinasewitz, GT, Janicki, JS, West, J, Henis, MMJ & Cohn, JN 1982, 'Hydralazine in the long-term treatment of chronic heart failure: Lack of difference from placebo', American Heart Journal, vol. 104, no. 3, pp. 587-594. https://doi.org/10.1016/0002-8703(82)90231-9
Franciosa, Joseph A. ; Weber, Karl ; Levine, T. Barry ; Kinasewitz, Gary T. ; Janicki, Joseph S. ; West, James ; Henis, Marc M.J. ; Cohn, Jay N. / Hydralazine in the long-term treatment of chronic heart failure : Lack of difference from placebo. In: American Heart Journal. 1982 ; Vol. 104, No. 3. pp. 587-594.
@article{ba3feac66caa46468e184bca7726cd7d,
title = "Hydralazine in the long-term treatment of chronic heart failure: Lack of difference from placebo",
abstract = "Although hydralazine improves cardiac performance in patients with chronic left ventricular failure, its long-term clinical efficacy has not been established in controlled trials. We carried out a double-blind randomized trial of hydralazine (200 mg daily in 16 patients) versus placebo (16 patients) in patients with class III and IV symptoms while they were taking digitalis and diuretics. Maximal treadmill exercise time was determined prior to and at 4, 10, 18, and 26 weeks of hydralazine or placebo treatment; average follow-up was 20 weeks. We found no change in body weight, clinical class, resting heart rate and blood pressure, or heart size (by chest x-ray examination and echocardiogram) during treatment in either group. The total number of complicating clinical events was insignificantly fewer in the hydralazine treated group (8 vs 13). Control exercise duration in the hydralazine group averaged 259 ± 21 seconds (SEM), and increased to 347 ± 35 seconds at 4 weeks (p < 0.01) and 421 ± 38 seconds at 26 weeks (p < 0.001). Exercise duration also increased significantly in the placebo group, from 271 ± 30 seconds at control to 340 ± 44 seconds at 4 weeks (p < 0.02) and 339 ± 46 seconds at 26 weeks (p < 0.02). No differences between groups were significant. Left ventricular ejection fraction remained depressed and unchanged in both groups. Thus long-term vasodilator treatment with hydralazine alone is not significantly more effective than placebo in chronic heart failure.",
author = "Franciosa, {Joseph A.} and Karl Weber and Levine, {T. Barry} and Kinasewitz, {Gary T.} and Janicki, {Joseph S.} and James West and Henis, {Marc M.J.} and Cohn, {Jay N.}",
year = "1982",
month = "1",
day = "1",
doi = "10.1016/0002-8703(82)90231-9",
language = "English (US)",
volume = "104",
pages = "587--594",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Hydralazine in the long-term treatment of chronic heart failure

T2 - Lack of difference from placebo

AU - Franciosa, Joseph A.

AU - Weber, Karl

AU - Levine, T. Barry

AU - Kinasewitz, Gary T.

AU - Janicki, Joseph S.

AU - West, James

AU - Henis, Marc M.J.

AU - Cohn, Jay N.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Although hydralazine improves cardiac performance in patients with chronic left ventricular failure, its long-term clinical efficacy has not been established in controlled trials. We carried out a double-blind randomized trial of hydralazine (200 mg daily in 16 patients) versus placebo (16 patients) in patients with class III and IV symptoms while they were taking digitalis and diuretics. Maximal treadmill exercise time was determined prior to and at 4, 10, 18, and 26 weeks of hydralazine or placebo treatment; average follow-up was 20 weeks. We found no change in body weight, clinical class, resting heart rate and blood pressure, or heart size (by chest x-ray examination and echocardiogram) during treatment in either group. The total number of complicating clinical events was insignificantly fewer in the hydralazine treated group (8 vs 13). Control exercise duration in the hydralazine group averaged 259 ± 21 seconds (SEM), and increased to 347 ± 35 seconds at 4 weeks (p < 0.01) and 421 ± 38 seconds at 26 weeks (p < 0.001). Exercise duration also increased significantly in the placebo group, from 271 ± 30 seconds at control to 340 ± 44 seconds at 4 weeks (p < 0.02) and 339 ± 46 seconds at 26 weeks (p < 0.02). No differences between groups were significant. Left ventricular ejection fraction remained depressed and unchanged in both groups. Thus long-term vasodilator treatment with hydralazine alone is not significantly more effective than placebo in chronic heart failure.

AB - Although hydralazine improves cardiac performance in patients with chronic left ventricular failure, its long-term clinical efficacy has not been established in controlled trials. We carried out a double-blind randomized trial of hydralazine (200 mg daily in 16 patients) versus placebo (16 patients) in patients with class III and IV symptoms while they were taking digitalis and diuretics. Maximal treadmill exercise time was determined prior to and at 4, 10, 18, and 26 weeks of hydralazine or placebo treatment; average follow-up was 20 weeks. We found no change in body weight, clinical class, resting heart rate and blood pressure, or heart size (by chest x-ray examination and echocardiogram) during treatment in either group. The total number of complicating clinical events was insignificantly fewer in the hydralazine treated group (8 vs 13). Control exercise duration in the hydralazine group averaged 259 ± 21 seconds (SEM), and increased to 347 ± 35 seconds at 4 weeks (p < 0.01) and 421 ± 38 seconds at 26 weeks (p < 0.001). Exercise duration also increased significantly in the placebo group, from 271 ± 30 seconds at control to 340 ± 44 seconds at 4 weeks (p < 0.02) and 339 ± 46 seconds at 26 weeks (p < 0.02). No differences between groups were significant. Left ventricular ejection fraction remained depressed and unchanged in both groups. Thus long-term vasodilator treatment with hydralazine alone is not significantly more effective than placebo in chronic heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0020426793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020426793&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(82)90231-9

DO - 10.1016/0002-8703(82)90231-9

M3 - Article

VL - 104

SP - 587

EP - 594

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -